Beruflich Dokumente
Kultur Dokumente
Health worker provides counselling on contraceptive methods to a couple, Papua New Guinea
WHO/Yoshi Shimizu
To guide contraceptive providers on the medical eligibility criteria (MEC) for contraceptive use, WHO uses a
four category system of eligibility as described in the table below. The full MEC guidance, contains more than
2000 recommendations for 25 different contraceptive methods, addresses more than 80 medical conditions or
personal characteristics, and is available online here
Category Condition
Category Condition
A condition for which there is no restriction for the use of the contraceptive
1 method
A condition where the advantages of using the method generally outweigh the
2 theoretical or proven risks
Note: In the “Medical eligibility criteria for contraceptive use” guideline, clarifications on eligibility are
provided for a number of medical conditions or personal characteristics.
Following the consultation in December 2016, WHO issued revised guidance for women at high risk of
acquiring HIV. The revised recommendation is that progestogen-only injectables (norethisterone enanthate
[NET-EN] and depot medroxyprogesterone acetate [DMPA, intramuscular or subcutaneous]) can be used by
women at high risk of HIV, because the advantages of these methods generally outweigh the possible, but
unproven, increased risk of HIV acquisition.
New Statement
The recommendation was previously a category 1 with a clarification, meaning there was no restriction for the
use of the contraceptive method but women should be informed that progestogen-only injectables may or may
not increase risk of HIV acquisition. This is now changed to a category 2; meaning women can use progestogen-
only injectables but should be advised about concerns that these methods may increase risk of HIV acquisition,
about the uncertainty over whether there is a causal relationship, and about how to minimize their risk of
acquiring HIV. This revised guidance places greater emphasis on the importance of shared decision making and
need for counselling on concerns that progestogen-only injectables may increase the risk of HIV infection.
Women at high risk of acquiring HIV can also use the following hormonal contraceptive methods without
restriction: combined oral contraceptive pills (COCs), combined injectable contraceptives (CICs), combined
contraceptive patches and rings, progestogen-only pills (POPs), and levonorgestrel (LNG) and etonogestrel
(ETG) implants (MEC category 1). This guidance remains unchanged.
For more information, please read the full statement on Hormonal Contraception and the risk of HIV acquisition
Medical eligibility criteria for contraceptive use
More information on WHO’s work on contraception and family planning
Statement